Sign In
Buy NDAQ
$77.65
-3.96 (-4.85%)
At Close: Jun 25, 2026
Vancouver, British Columbia--(Newsfile Corp. - November 5, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of pro
TransCode Therapeutics Announces Nasdaq Extension to Regain Compliance
07:00am, Tuesday, 05'th Nov 2024
BOSTON, Nov. 05, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced th
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07:00am, Tuesday, 05'th Nov 2024
RESEARCH TRIANGLE PARK, N.C., Nov. 05, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted f
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:44pm, Monday, 04'th Nov 2024
SAN FRANCISCO, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, d
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:15pm, Monday, 04'th Nov 2024
WALTHAM, Mass and DUBLIN, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Monday, 04'th Nov 2024
SAN DIEGO, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent s
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:00pm, Monday, 04'th Nov 2024
WESTLAKE VILLAGE, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in
3-Stock Lunch: Trump Media, KBW Bank & First Trust Nasdaq Cybersecurity
03:22pm, Monday, 04'th Nov 2024
Jay Woods, Freedom Capital Markets chief global strategist, joins 'Power Lunch' to discuss stock plays for three stocks.
S&P 500 and Nasdaq 100: Market Holds Steady as U.S. Election and Fed Decision Loom
09:47am, Monday, 04'th Nov 2024
With a close U.S. election and Fed rate cuts likely, stock market sentiment hangs in the balance. Key decisions could sway year-end trading trends.
Nasdaq, Dow Jones and S&P 500 Forecast – US Stocks Wait for Elections and Fed
08:43am, Monday, 04'th Nov 2024
The US Indices are currently treading water, as we wait for the overall direction to be determined via elections night, and of course the Fed decision on Thursday. At this point, the markets are simpl
Banzai Announces Listing Transfer to Nasdaq Capital Market Pursuant to Nasdaq Compliance Plan
08:31am, Monday, 04'th Nov 2024
SEATTLE, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Banzai International, Inc. (NASDAQ: BNZI) (“Banzai” or the “Company”), a leading marketing technology company that provides essential marketing and s
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07:04pm, Friday, 01'st Nov 2024
SAN DIEGO, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small mole
DevvStream Provides Update on Previously Announced Business Combination and Nasdaq Listing
07:02pm, Friday, 01'st Nov 2024
DevvStream's business combination with Focus Impact Acquisition Corp. and uplisting to the Nasdaq continues to progress towards completion Vancouver, British Columbia--(Newsfile Corp. - November 1, 20
APX Acquisition Corp. I Announces Nasdaq Delisting Notification for Warrants and Units
05:48pm, Friday, 01'st Nov 2024
NASHVILLE, Tenn. , Nov. 1, 2024 /PRNewswire/ -- As previously announced, on September 4, 2024, APX Acquisition Corp. I (NASDAQ: APXI ) (the "Company"), received a written notice from the Listing Qua
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05:26pm, Friday, 01'st Nov 2024
NAARDEN, The Netherlands and MIAMI, Nov. 01, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutic
